

**Baxter International Inc.**  
**Key Product Line Sales**  
**Period Ended September 30, 2006**  
**(unaudited)**  
**(\$ in millions)**

	Q3 2006	Q3 2005 <sup>1</sup>	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2006	YTD 2005 <sup>1</sup>	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>								
Recombinants	\$433	\$392	10%	8%	\$1,244	\$1,133	10%	11%
Plasma Proteins <sup>2</sup>	214	176	22%	19%	619	516	20%	21%
Antibody Therapy	196	123	59%	57%	578	305	90%	90%
BioSurgery <sup>3</sup>	72	63	14%	13%	220	199	11%	12%
Transfusion Therapies	121	134	(10%)	(11%)	371	407	(9%)	(8%)
Other <sup>4</sup>	52	62	(16%)	(16%)	177	282	(37%)	(35%)
<b>Total BioScience</b>	<b>\$1,088</b>	<b>\$950</b>	<b>15%</b>	<b>13%</b>	<b>\$3,209</b>	<b>\$2,842</b>	<b>13%</b>	<b>14%</b>
<b>Medication Delivery</b>								
IV Therapies <sup>5</sup>	\$317	\$301	5%	4%	\$944	\$909	4%	5%
Drug Delivery	205	192	7%	5%	613	622	(1%)	(1%)
Infusion Systems	197	184	7%	7%	596	659	(10%)	(9%)
Anesthesia and Injectable Drugs	221	259	(15%)	(15%)	691	772	(10%)	(10%)
Other <sup>6</sup>	10	21	(52%)	(48%)	34	56	(39%)	(38%)
<b>Total Medication Delivery</b>	<b>\$950</b>	<b>\$957</b>	<b>(1%)</b>	<b>(2%)</b>	<b>\$2,878</b>	<b>\$3,018</b>	<b>(5%)</b>	<b>(4%)</b>
<b>Renal</b>								
PD Therapy	\$409	\$386	6%	6%	\$1,205	\$1,153	5%	6%
HD Therapy	110	105	5%	5%	323	345	(6%)	(6%)
<b>Total Renal<sup>7</sup></b>	<b>\$519</b>	<b>\$491</b>	<b>6%</b>	<b>5%</b>	<b>\$1,528</b>	<b>\$1,498</b>	<b>2%</b>	<b>3%</b>
<b>TOTAL BAXTER</b>	<b>\$2,557</b>	<b>\$2,398</b>	<b>7%</b>	<b>6%</b>	<b>\$7,615</b>	<b>\$7,358</b>	<b>3%</b>	<b>4%</b>

<sup>1</sup> Prior year sales data has been reclassified to reflect the changes that are described in notes 2, 3, 4 and 7 below.

<sup>2</sup> Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products. Sales of Tisseel, sales of plasma to third parties, and contract manufacturing revenues were previously reported in Plasma Proteins, and are now reported in other product lines, as detailed below.

<sup>3</sup> Includes sales of Tisseel and FloSeal/CoSeal, which were previously reported in Plasma Proteins and Other, respectively.

<sup>4</sup> Principally includes vaccines and sales of plasma to third parties. The sales of plasma to third parties were previously reported in Plasma Proteins. The prior year sales include contract manufacturing revenues.

<sup>5</sup> Principally includes intravenous solutions and nutritional products.

<sup>6</sup> Principally includes other hospital-distributed products.

<sup>7</sup> Sales of pharmaceutical and certain other products, which were previously reported in Other, are now reported in PD Therapy.